Vancouver, Canada – Virogin Biotech (“Virogin”) is pleased to announce it has recently signed an agreement with China National Biotec Group (CNBG) to create a Joint Venture that will focus on the research & development, clinical development, and commercialization of oncolytic virotherapies. The new company will be based at the Precision Medicine Industrial Park located in Nanxiang, Shanghai.
The Virogin-CNBG Joint Venture will combine Virogin’s expertise in oncolytic virology and its HSV-1 based platform technology with CNBG’s deep clinical development, manufacturing, and distribution capabilities, in a bid to develop novel cancer immunotherapies for the Greater China market. CNBG is the biological product arm of Sinopharm, China’s largest pharmaceutical and healthcare group. Chris Huang, Virogin’s CEO & Co-founder, commented, “We are very excited to be working with a reputable organization like CNBG to accelerate the development of our oncolytic virus products to meet the critical needs of patients in China.”
About Virogin Biotech
Virogin Biotech (Virogin) is a biotechnology company that specialized in innovating immuno-oncolytic therapeutics. Virogin is developing novel cancer immunotherapies using its targeted gene delivery platform based on an engineered oncolytic HSV-1 as a vector for robust and controlled expression of immune-modulating payloads to maximize efficacy while minimizing toxicity. Founded in 2015, Virogin is a Vancouver-based company with a leadership team of veterans in oncolytic virus research and product development. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.
About China National Biotec Group
China National Biotec Group (CNBG) is the biological product arm of Sinopharm, China’s largest pharmaceutical and healthcare group in China, with core business in pharmaceutical distribution, scientific research and manufacture of medical and biotech products. CNBG is the leading vaccine manufacturer in China, having multiple production sites in 8 major Chinese cities, focusing on R&D, manufacture and marketing of biological products. The portfolio of CNBG includes vaccines, plasma-derived products, as well as medical aesthetics products and diagnostic reagents.